Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Average Price Target from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $11.13.

STRO has been the topic of a number of recent analyst reports. JMP Securities reissued a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Wedbush reissued an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a research report on Tuesday, December 10th. Wells Fargo & Company reduced their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and set a $11.00 price target on shares of Sutro Biopharma in a report on Friday, October 11th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a research note on Monday, November 18th.

Hedge Funds Weigh In On Sutro Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. ProShare Advisors LLC lifted its position in shares of Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after buying an additional 5,373 shares during the last quarter. Hsbc Holdings PLC raised its stake in Sutro Biopharma by 9.7% in the 2nd quarter. Hsbc Holdings PLC now owns 60,858 shares of the company’s stock valued at $173,000 after acquiring an additional 5,404 shares during the period. SG Americas Securities LLC lifted its holdings in Sutro Biopharma by 16.6% during the fourth quarter. SG Americas Securities LLC now owns 40,432 shares of the company’s stock valued at $74,000 after purchasing an additional 5,770 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Sutro Biopharma by 27.4% during the second quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after purchasing an additional 7,082 shares during the period. Finally, Gladius Capital Management LP purchased a new position in shares of Sutro Biopharma in the third quarter worth about $28,000. 96.99% of the stock is owned by institutional investors.

Sutro Biopharma Trading Up 3.0 %

Shares of NASDAQ:STRO opened at $2.03 on Friday. The stock has a market cap of $167.39 million, a PE ratio of -1.26 and a beta of 1.15. The stock’s fifty day simple moving average is $2.22 and its two-hundred day simple moving average is $3.31. Sutro Biopharma has a 1-year low of $1.67 and a 1-year high of $6.13.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.